Alzheon's Reclaimed Alzheimer's Drug Has Potential To Win Big – If History Doesn't Repeat

New data for Alzheon's Alzheimer's disease drug, tramiprosate, from two Phase III trials that failed to show efficacy in 2007 may shed light on how the company can better design new trials for follow-on product ALZ-801, for which it will initiate pivotal Phase III studies next year.